

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Modak et al.

Appln. No.

10/600,257

Examiner

Azpuru, Carlos A.

Filed

June 20, 2003

Group Art Unit :

1615

For

ANTIMICROBIAL MEDICAL DEVICES

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 21, 2005

Date of Deposit

Peter J. Shen

52,217

Patent Reg. No.

March 21, 2005 Date of Signature

Signature

Commissioner for Patents P.O. Box 1450

Mail Stop Amendment

Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the enclosed Form PTO-1449 and respectfully request that the listed documents be considered by the Examiner and made of record in the above-captioned application. Copies of the international search report and written opinion issued in the parent international application (No. PCT/US01/49205) are enclosed herewith. Copies of all foreign patent documents and literature references listed on the enclosed Form PTO-1449 are currently being collected and will follow shortly.

NY02:515266.1

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits of referenced application. Therefore, Applicants enclose the fee due in connection with the submission of this paper. If any additional fee is due, or if any overpayment has been made, the Commissioner is authorized to charge any such fee or credit any overpayment, to our Deposit Account No. 02-4377.

Respectfully submitted,

BAKER BOTTS L.L.P.

By:

Peter J. Shen

Patent Office Reg. No. 52,217 30 Rockefeller Plaza, 44th Floor New York, NY 10012-4498

Attorney for Applicants

212-408-2500

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTS OF THE

Atty. Docket No. 33432-A-PCT-USA-A (070050.2407) Serial No. 10/600,257

Applicants Modak et al.

Filing Date
June 20, 2003

Group Art Unit 1615

U.S. PATENT DOCUMENTS

*Exam. Init.			Docun	nent N	0.			Date	Name	Class	Subclass	Filing Date ifAppropriate
	 4	6	0	5	5	6	4	08/12/86	Kulla et al.	427	2.3	
	4	7	2	3	9	5	0	02/09/88	Lee	604	322	
	 4	9	9	9	2	1	0	03/12/91	Solomon et al.	427	2	
	4	9	9	4	0	4	7	02/19/91	Walker et al.	604	264	
	5	0	1	3	3	0	6	05/07/91	Solomon et al.	604	265	
	5	0	1	9	0	9	6	05/28/91	Fox, Jr. et al.	600	36	
	5	0	3	3	4	8	8	07/23/91	Curtis et al.	132	321	
	5	0	8	9	2	0	5	02/18/92	Huang et al.	264	255	*
	5	0	9	1	4	4	2	02/25/92	Milner	523	122	
	5	1	0	2	4	0	1	04/07/92	Lambert et al.	604	264	
	5	1	6	5	9	5	2	11/24/92	Solomon et al.	427	2.25	
	5	1	8	0	6	0	5	01/19/93	Milner	427	2.3	
	5	2	0	0	1	9	4	04/06/93	Edgren et al.	424	473	
	5	2	0	9	2	5	1	05/11/93	Curtis et al.	132	321	
	5	2	6	1	4	2	1	11/16/93	Milner	128	898	
	5	3	5	7	6	3	6	10/25/94	Dangman et al.	2	161.7	
	5	3	3	5	3	7	3	08/09/94	Dangman et al.	2	161.7	
	5	3	5	7	6	3	6	10/25/94	Dresdner, Jr. et al.	2	161.7	
	5	4	2	0	1	9	7	05/30/95	Lorenz et al.	525	54.3	
	5	4	5	1	4	2	4	09/19/95	Solomon et al.	427	2.1	
	5	6	1	6	3	3	8	04/01/97	Fox Jr. et al.	424	423	
	5	7	0	7	3	6	6	01/13/98	Solomon et al.	604	265	

Examiner

Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant. NY02:515265.1

Page 2 of 3 Form PTO-1449 U.S. Department of Commerce Serial No. Atty. Docket No. (REV. 2-82) Patent and Trademark Office 33432-A-PCT-USA-A 10/600,257 (070050.2407) INFORMATION DISCLOSURE STATEMENT **Applicants** BY APPLICANTS Modak et al. Filing Date Group Art Unit June 20, 2003 06/30/98 Modak et al. 07/04/00 Modak et al. 08/22/00 Modak et al. 05/01/01 Modak et al. 07/17/01 Solomon et al. 09/30/03 Modak et al. FOREIGN PATENT DOCUMENT **Translator** Date Class SubClass Yes No Document No. Country EP 08/16/89 07/25/90 EP 08/21/91 EP 04/15/93 WO WO 02/18/93 05/30/95 EP WO 07/25/96 07/17/97 WO 02/23/99 JP 10/05/00 WO OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.) The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, Tenth Edition Merck & Co., Inc., Rahway, NJ, 1983, p. 1092. Examiner **Date Considered**

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant. NY02:515265.1

	Atty. Docket No. 33432-A-PCT-USA-A (070050.2407)	Serial No. 10/600,257							
	Applicants Modak et al.								
	Filing Date June 20, 2003	Group Art Unit 1615							
Prevention of bacterial colonization of olyurethane polymers.	intravenous catheters by a	ntiseptic impregnation of							
Choi L, Choudhri AF, Pillarisetty VG, Sampath LA, Caraos L, Brunnert SR, Oz MC, Modak SM. Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. J Heart Lung Transplant. 1999 Nov;18(11):1103-10.									
Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother. 2001 May;47(5):589-98.									
Kim CY, Kumar A, Sampath L, Sokol K, Modak S. Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats. Am J Kidney Dis. 2002 Jan;39(1):165-73.									
valuation of the antimicrobial efficacy itro urinary tract model.	y of urinary catheters impr	egnated with antiseptics in an in							
Serial No. 09/746,670), a triple lumen ne United States. This catheter had an ercent (3%) weight by volume (w/v) oulfadiazine. The catheter had an inner olvent ethanol, 0.75 percent (0.75%) v	catheter was sold by the li outer coating prepared us of chlorhexidine diacetate a lumen coating prepared u	icensee, Arrow Incorporated, in ing a solution containing three and 0.75 percent w/v silver using a solution containing the							
	Prevention of bacterial colonization of olyurethane polymers. Antimicrob Chemother. 1994 May;33 Choi L, Choudhri AF, Pillarisetty VG, Development of an infection-resistant levice-related infections. Heart Lung Transplant. 1999 Nov;186 Cambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of development devices. Antimicrob Chemother. 2001 May;47 Cim CY, Kumar A, Sampath L, Sokol Evaluation of an antimicrobial-impregnance fection control in rats. In J Kidney Dis. 2002 Jan;39(1):165-165 Gaonkar TA, Sampath LA, Modak SM, Evaluation of the antimicrobial efficacy intro urinary tract model. Infect Control Hosp Epidemiol. 2003 Jun April 17, 2000, which is prior to the Serial No. 09/746,670), a triple lument the United States. This catheter had an inner unifadiazine. The catheter had an inner unifadiazine. The catheter had an inner catheter	Applicants Modak et al. Filing Date June 20, 2003 Bach A, Bohrer H, Motsch J, Martin E, Geiss HK, Sonntag HG. Prevention of bacterial colonization of intravenous catheters by a colyurethane polymers. Antimicrob Chemother. 1994 May;33(5):969-78. Choi L, Choudhri AF, Pillarisetty VG, Sampath LA, Caraos L, B cevelopment of an infection-resistant LVAD driveline: a novel a cevice-related infections. Heart Lung Transplant. 1999 Nov;18(11):1103-10. Fambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to in medical devices. Antimicrob Chemother. 2001 May;47(5):589-98. Clim CY, Kumar A, Sampath L, Sokol K, Modak S. Evaluation of an antimicrobial-impregnated continuous ambulator infection control in rats. Sum J Kidney Dis. 2002 Jan;39(1):165-73. Gaonkar TA, Sampath LA, Modak SM. Evaluation of the antimicrobial efficacy of urinary catheters imprint ourinary tract model. Infect Control Hosp Epidemiol. 2003 Jul;24(7):506-13. On April 17, 2000, which is prior to the December 22, 2000 filing Serial No. 09/746,670), a triple lumen catheter was sold by the life United States. This catheter had an outer coating prepared us ercent (3%) weight by volume (w/v) of chlorhexidine diacetate a culfadiazine. The catheter had an inner lumen coating prepared us colvent ethanol, 0.75 percent (0.75%) w/v chlorhexidine free base							

Examiner Date Considered

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant. NY02:515265.1